Phase I open label study to determine safety, tolerability and pharmacokinetics of single and repeated doses of F351
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
Price : $35 *
At a glance
- Drugs Hydronidone (Primary)
- Indications Hepatic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 24 Apr 2018 According to a GNI media release, this trial is expected to be completed by the second half of 2018.
- 24 Apr 2018 According to a GNI media release, first patient has been dosed.
- 24 Apr 2018 Status changed from planning to recruiting, according to a GNI media release.